TD
MCID: TRD006
MIFTS: 60

Tardive Dyskinesia (TD)

Categories: Gastrointestinal diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Tardive Dyskinesia

MalaCards integrated aliases for Tardive Dyskinesia:

Name: Tardive Dyskinesia 57 76 53 54 29 73
Neuroleptic-Induced Tardive Dyskinesia 73
Lingual-Facial-Buccal Dyskinesia 73
Drug-Induced Tardive Dyskinesia 73
Linguofacial Dyskinesia 53
Tardive Oral Dyskinesia 53
Tardive Dystonia 53
Td 53

Characteristics:

OMIM:

57
Inheritance:
autosomal recessive predisposition


HPO:

32
tardive dyskinesia:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 57 272620
MedGen 42 C0686347
SNOMED-CT via HPO 69 258211005

Summaries for Tardive Dyskinesia

NIH Rare Diseases : 53 Tardive dyskinesia is a neurological movement disorder that is caused by the long-term use of a certain type of medications called neuroleptics. Neuroleptic drugs are usually prescribed for psychiatric conditions, although they may be used to treat gastrointestinal or neurological conditions in some cases. Tardive dyskinesia is primarily characterized by repetitive involuntary movements of the jaw, lips and tongue such as grimacing; sticking out the tongue; and smacking, puckering and pursing the lips. Some affected people may also experience involuntary rapid, jerking movements (chorea) or slow, writhing movements (athetosis) of the arms and/or legs. It is unclear why some people who take neuroleptic medications develop these symptoms while others do not. Treatment for this condition varies but may include stopping or minimizing the use of neuroleptic drugs and/or taking additional medications to to reduce the severity of the symptoms.

MalaCards based summary : Tardive Dyskinesia, also known as neuroleptic-induced tardive dyskinesia, is related to schizophrenia and neuroleptic malignant syndrome, and has symptoms including myoclonus and spasmodic torticollis. An important gene associated with Tardive Dyskinesia is NQO1 (NAD(P)H Quinone Dehydrogenase 1), and among its related pathways/superpathways are Glucose / Energy Metabolism and Monoamine GPCRs. The drugs Aripiprazole and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include tongue, eye and brain, and related phenotypes are tardive dyskinesia and akathisia

OMIM : 57 Tardive dyskinesia is a debilitating motor disorder manifest as hyperkinetic, involuntary, repetitive movements predominantly of the orofacial region. It is a complication of treatment with so-called typical antipsychotic or neuroleptic agents, such as chlorpromazine or haloperidol, and is estimated to occur in 20 to 30% of chronic schizophrenics on long-term treatment (Thelma et al., 2008). (272620)

NINDS : 54 Tardive dyskinesia is a neurological syndrome caused by the long-term use of neuroleptic drugs. Neuroleptic drugs are generally prescribed for psychiatric disorders, as well as for some gastrointestinal and neurological disorders. Tardive dyskinesia is characterized by repetitive, involuntary, purposeless movements. Features of the disorder may include grimacing, tongue protrusion, lip smacking, puckering and pursing, and rapid eye blinking. Rapid movements of the arms, legs, and trunk may also occur. Involuntary movements of the fingers may be present.

Wikipedia : 76 Tardive dyskinesia (TD) is a disorder that results in involuntary, repetitive body movements. This may... more...

Related Diseases for Tardive Dyskinesia

Diseases related to Tardive Dyskinesia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 113)
# Related Disease Score Top Affiliating Genes
1 schizophrenia 30.6 COMT CYP1A2 CYP2D6 DRD2 DRD3 HTR2A
2 neuroleptic malignant syndrome 30.2 CYP2D6 DRD2
3 mood disorder 30.1 COMT DRD2 DRD3 HTR2A
4 bipolar i disorder 30.0 COMT HTR2A
5 bipolar disorder 29.9 COMT DRD2 DRD3 HTR2A
6 major depressive disorder 29.8 COMT CYP2D6 DRD2 DRD3 HTR2A
7 schizoaffective disorder 29.8 COMT DRD2 DRD3 HTR2A
8 substance abuse 29.8 COMT CYP2D6 DRD2 DRD3
9 megacolon 29.7 DRD2 HTR2A
10 attention deficit-hyperactivity disorder 29.3 COMT CYP2D6 DRD2 DRD3 HTR2A
11 drug induced dyskinesia 11.6
12 dystonia 10.7
13 depression 10.6
14 major affective disorder 1 10.4
15 major affective disorder 8 10.4
16 major affective disorder 7 10.4
17 major affective disorder 9 10.4
18 tremor 10.4
19 gilles de la tourette syndrome 10.4
20 dementia 10.3
21 movement disease 10.3
22 aging 10.3
23 alzheimer disease 10.2
24 lymphedema, hereditary, ii 10.2
25 alacrima, achalasia, and mental retardation syndrome 10.2
26 diabetes mellitus 10.2
27 hypothyroidism 10.2
28 impulse control disorder 10.1 DRD2 DRD3
29 galactorrhea 10.1 CYP2D6 DRD2
30 schizophreniform disorder 10.1 COMT DRD2
31 migraine without aura 10.1 DRD2 DRD3
32 opiate dependence 10.1 DRD2 DRD3
33 oppositional defiant disorder 10.1 COMT DRD2
34 alexithymia 10.1 COMT DRD2
35 opioid addiction 10.1 COMT DRD2
36 traumatic brain injury 10.1 COMT DRD2
37 brain injury 10.1 COMT DRD2
38 antisocial personality disorder 10.0 COMT DRD2
39 amelogenesis imperfecta, type ib 10.0 CYP1A2 CYP2D6
40 toxicity or absent response to clozapine 10.0 COMT CYP1A2
41 female stress incontinence 10.0 CYP1A2 CYP2D6
42 gastroparesis 10.0 CYP2D6 DRD2
43 diabetes mellitus, noninsulin-dependent 10.0
44 multiple sclerosis 10.0
45 dementia, lewy body 10.0
46 huntington disease 10.0
47 schizophrenia 1 10.0
48 torticollis 10.0
49 choreoacanthocytosis 10.0
50 graves disease 1 10.0

Comorbidity relations with Tardive Dyskinesia via Phenotypic Disease Network (PDN): (show all 16)


Acute Cystitis Alzheimer Disease
Anxiety Bipolar Disorder
Decubitus Ulcer Deficiency Anemia
Dysthymic Disorder Esophagitis
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Paranoid Schizophrenia
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Schizophrenia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Tardive Dyskinesia:



Diseases related to Tardive Dyskinesia

Symptoms & Phenotypes for Tardive Dyskinesia

Symptoms via clinical synopsis from OMIM:

57
Neuro:
tardive dyskinesia
repetitive rapid body movements
chewing movements
oral-lingual-buccal dyskinesia
tongue darting
more
Misc:
complication of treatment with neuroleptic agents


Clinical features from OMIM:

272620

Human phenotypes related to Tardive Dyskinesia:

32
# Description HPO Frequency HPO Source Accession
1 tardive dyskinesia 32 HP:0040141
2 akathisia 32 HP:0031943

UMLS symptoms related to Tardive Dyskinesia:


myoclonus, spasmodic torticollis

MGI Mouse Phenotypes related to Tardive Dyskinesia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.8 COMT CYP1A2 DRD2 DRD3 HSPG2 HTR2A
2 cardiovascular system MP:0005385 9.63 COMT CYP1A2 DRD2 DRD3 HSPG2 SOD2
3 homeostasis/metabolism MP:0005376 9.5 COMT CYP1A2 DRD2 DRD3 HSPG2 NQO1
4 liver/biliary system MP:0005370 9.02 CYP1A2 DRD2 HSPG2 NQO1 SOD2

Drugs & Therapeutics for Tardive Dyskinesia

Drugs for Tardive Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
2
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
3
Zolpidem Approved Phase 4 82626-48-0 5732
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
5 tannic acid Approved Phase 4
6
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
7
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
8
Galantamine Approved Phase 4 357-70-0 9651
9
Lithium carbonate Approved Phase 4 554-13-2
10
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
11
Nicotine Approved Phase 4 54-11-5 942 89594
12
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
13
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
14
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
15
Tetrabenazine Approved, Investigational Phase 4,Phase 3,Phase 2 58-46-8 6018
16
Haloperidol Approved Phase 4 52-86-8 3559
17
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
18
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
19
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
20
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
21 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 GABA-A Receptor Agonists Phase 4
26 GABA Agonists Phase 4
27 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
28 Hypnotics and Sedatives Phase 4
29 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1
30 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
32 GABA Agents Phase 4
33 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Omega 3 Fatty Acid Phase 4,Phase 2
35 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2
36 sultopride Phase 4
37 Autonomic Agents Phase 4,Phase 2,Phase 1
38 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
39 Antiemetics Phase 4,Phase 2,Phase 1
40 Gastrointestinal Agents Phase 4,Phase 2,Phase 1
41 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 1
42 Nootropic Agents Phase 4,Phase 3,Phase 2
43 Cholinergic Agents Phase 4,Phase 1,Phase 2
44 Cholinesterase Inhibitors Phase 4
45 Antimanic Agents Phase 4
46 Antidepressive Agents Phase 4
47 Antidepressive Agents, Second-Generation Phase 4
48 Cytochrome P-450 Enzyme Inhibitors Phase 4
49 Dopamine Uptake Inhibitors Phase 4
50 Cytochrome P-450 CYP2D6 Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 74)
# Name Status NCT ID Phase Drugs
1 Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia Unknown status NCT00837707 Phase 4 aripiprazole
2 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
3 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4 Risperidone and Zolpidem for delirium
4 Tardive Dyskinesia and Cognitive Function Completed NCT00926965 Phase 4 amisulpride;Olanzapine;Conventional antipsychotics
5 Treatment of Tardive Dyskinesia With Galantamine Completed NCT00164242 Phase 4 Galantamine
6 Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia Completed NCT00621998 Phase 4 risperidone;olanzapine
7 Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia Completed NCT00114595 Phase 4 eicosapentaenoic acid
8 Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features Completed NCT00202293 Phase 4 Olanzapine;Lithium;Chlorpromazine
9 The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia Completed NCT00495352 Phase 4 Hihg-doseNRT, Low-dose NRT, bupropion
10 Study of Vitamin D in the Severely Mentally Ill Completed NCT01169142 Phase 4
11 Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics Completed NCT00458211 Phase 4 ziprasidone
12 A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00206102 Phase 4 quetiapine fumarate;risperidone
13 Antipsychotic Discontinuation in Alzheimer's Disease Completed NCT00417482 Phase 4 risperidone
14 Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women Completed NCT01937234 Phase 4 Metoclopramide;Placebo
15 The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Recruiting NCT03698331 Phase 4 Valbenazine;Placebo oral capsule
16 Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia Recruiting NCT03323437 Phase 4 Risperidone
17 Agents Intervening Against Delirium in Intensive Care Unit Recruiting NCT03392376 Phase 4 Haloperidol Injection
18 Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates Not yet recruiting NCT03495024 Phase 4 Varenicline
19 Addressing Involuntary Movements in Tardive Dyskinesia Completed NCT02291861 Phase 3 SD-809;Placebo
20 Aim to Reduce Movements in Tardive Dyskinesia Completed NCT02195700 Phase 2, Phase 3 SD-809;Placebo
21 A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02274558 Phase 3 NBI-98854;Placebo
22 Piracetam for Treatment Tardive Dyskinesia Completed NCT00190008 Phase 3 piracetam
23 Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia Completed NCT02736955 Phase 3 Valbenazine
24 Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02405091 Phase 3 NBI-98854
25 Extract of Ginkgo Biloba and Tardive Dyskinesia Completed NCT00672373 Phase 3 Extract of Ginkgo Biloba (EGb-761 capsules);Placebo
26 Levetiracetam Treatment of Tardive Dyskinesia Completed NCT00291213 Phase 3 levetiracetam;placebo
27 Xenazine in Late Dyskinetic Syndrome With Neuroleptics Completed NCT01543321 Phase 3 Tetrabenazine;Placebo
28 A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia Completed NCT00210769 Phase 3 paliperidone ER Oros
29 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal
30 Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type Completed NCT01438060 Phase 3 Aripiprazole (BMS-337039);Placebo
31 High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms Completed NCT00403546 Phase 3 Ziprasidone 80-160 mg/d;Placebo;Ziprasidone 160 mg/d
32 Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia Recruiting NCT03176771 Phase 2, Phase 3 MT-5199;Placebo
33 Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia Recruiting NCT03254186 Phase 2, Phase 3 Propranolol Hydrochloride;Placebo Oral Tablet
34 Reducing Involuntary Movements in Tardive Dyskinesia Active, not recruiting NCT02198794 Phase 3 SD-809;Placebo
35 Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Not yet recruiting NCT03790345 Phase 2, Phase 3 Pyridoxine;Cobalamin;Placebo Oral Tablet
36 A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents Not yet recruiting NCT03813238 Phase 3 Deutetrabenazine;Placebo
37 Pyridoxal Kinase Activity in Tardive Dyskinesia Withdrawn NCT01908452 Phase 3 Pyridoxine
38 Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia Unknown status NCT00621634 Phase 2
39 Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia Unknown status NCT00331669 Phase 2
40 Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia Completed NCT01267188 Phase 2 NBI-98854
41 A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia Completed NCT02064010 Phase 2 SNC-102;Placebo
42 NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia Completed NCT01733121 Phase 2 NBI-98854;NBI-98854;Placebo
43 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) Completed NCT01688037 Phase 2 NBI-98854;NBI-98854;Placebo
44 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT01393600 Phase 2 NBI-98854;NBI-98854;Placebo
45 Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia Completed NCT00175955 Phase 2 Levetiracetam
46 Dysport for the Treatment of OMD Completed NCT01921270 Phase 1, Phase 2 Low Dose - AbobotulinumtoxinA
47 Heart Rate Variability in Response to Metformin Challenge Completed NCT02500628 Phase 2 Metformin
48 Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia Completed NCT00401089 Phase 1, Phase 2 Panax Ginseng
49 Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy Completed NCT01677377 Phase 2 Risperidone;RBP-7000
50 Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia Completed NCT01176721 Phase 2

Search NIH Clinical Center for Tardive Dyskinesia

Genetic Tests for Tardive Dyskinesia

Genetic tests related to Tardive Dyskinesia:

# Genetic test Affiliating Genes
1 Tardive Dyskinesia 29

Anatomical Context for Tardive Dyskinesia

MalaCards organs/tissues related to Tardive Dyskinesia:

41
Tongue, Eye, Brain, Bone, Heart, Globus Pallidus, Subthalamic Nucleus

Publications for Tardive Dyskinesia

Articles related to Tardive Dyskinesia:

(show top 50) (show all 1116)
# Title Authors Year
1
Lithium monotherapy-induced tardive dyskinesia. ( 30321768 )
2019
2
Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia. ( 29433806 )
2018
3
Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies. ( 29427000 )
2018
4
Tardive dyskinesia responsive to deep brain stimulation. ( 29506398 )
2018
5
Effectiveness and Value of 2 Novel Treatments for Tardive Dyskinesia. ( 29913006 )
2018
6
What You Should Know About Tardive Dyskinesia: Screening, Causes, and New Treatment Options. ( 29505191 )
2018
7
Tardive dyskinesia: Epidemiology. ( 29433811 )
2018
8
Vesicular monoamine transporter type 2 inhibition can lead to effective and tolerable management of tardive dyskinesia. ( 29945944 )
2018
9
VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia. ( 29609698 )
2018
10
Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. ( 29557243 )
2018
11
Tardive Dyskinesia: Is Vitamin E Singing the Prostate Blues? ( 29701932 )
2018
12
Two New Drugs for Tardive Dyskinesia Hit the Market. ( 29369770 )
2018
13
Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia. ( 29667946 )
2018
14
Valbenazine as the first and only approved treatment for adults with tardive dyskinesia. ( 29338466 )
2018
15
Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. ( 29409162 )
2018
16
VMAT2 inhibitors for the treatment of tardive dyskinesia. ( 29433808 )
2018
17
Future directions in tardive dyskinesia research. ( 29433809 )
2018
18
Correction to: Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. ( 29524074 )
2018
19
Miscellaneous treatments for antipsychotic-induced tardive dyskinesia. ( 29552749 )
2018
20
The importance of clinical observation: A case of subtle tardive dyskinesia with paliperidone palmitate. ( 29338294 )
2018
21
Altered serum levels of glial cell line-derived neurotrophic factor in male chronic schizophrenia patients with tardive dyskinesia. ( 29901253 )
2018
22
Vitamin E for antipsychotic-induced tardive dyskinesia. ( 29341067 )
2018
23
Reprint of: Clinical management of tardive dyskinesia: Five steps to success. ( 29519687 )
2018
24
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. ( 29795977 )
2018
25
Clinical risk factors for the development of tardive dyskinesia. ( 29439776 )
2018
26
Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia. ( 29663328 )
2018
27
Resting-state Brain Activity Changes Associated with Tardive Dyskinesia in Patients with Schizophrenia: Fractional Amplitude of Low-frequency Fluctuation Decreased in the Occipital Lobe. ( 29909076 )
2018
28
Cholinergic medication for antipsychotic-induced tardive dyskinesia. ( 29553158 )
2018
29
Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia. ( 29342497 )
2018
30
Anticholinergic medication for antipsychotic-induced tardive dyskinesia. ( 29341071 )
2018
31
Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis. ( 29570969 )
2018
32
Benzodiazepines for antipsychotic-induced tardive dyskinesia. ( 29352477 )
2018
33
Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop. ( 29742330 )
2018
34
Calcium channel blockers for antipsychotic-induced tardive dyskinesia. ( 29578611 )
2018
35
Amisulpride Reexposure and Tardive Dyskinesia. ( 29403138 )
2018
36
Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia. ( 29896031 )
2018
37
Deuterium Tetrabenazine for Tardive Dyskinesia. ( 29341821 )
2018
38
Frequency and correlates of tardive dyskinesia in Indian patients with type I bipolar disorder. ( 29222987 )
2018
39
Quantitative DNA Methylation Analysis of DLGAP2 Gene using Pyrosequencing in Schizophrenia with Tardive Dyskinesia: A Linear Mixed Model Approach. ( 30504779 )
2018
40
Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia. ( 30118782 )
2018
41
Decreased Gray Matter Volume of Cuneus and Lingual Gyrus in Schizophrenia Patients with Tardive Dyskinesia is Associated with Abnormal Involuntary Movement. ( 30150749 )
2018
42
Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review. ( 28965423 )
2018
43
Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less "go" and more "stop" from the motor striatum for robust therapeutic effects. ( 29249207 )
2018
44
Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study. ( 29324468 )
2018
45
Tardive dyskinesia: Out of the shadows. ( 29449008 )
2018
46
Historical perspectives on tardive dyskinesia. ( 29454494 )
2018
47
VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications. ( 29455579 )
2018
48
Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. ( 29484607 )
2018
49
Genetics of tardive dyskinesia: Promising leads and ways forward. ( 29502799 )
2018
50
Discussing the Risk of Tardive Dyskinesia With Patients and Screening for Signs. ( 29505187 )
2018

Variations for Tardive Dyskinesia

Expression for Tardive Dyskinesia

Search GEO for disease gene expression data for Tardive Dyskinesia.

Pathways for Tardive Dyskinesia

Pathways related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1 12.11 CYP1A2 CYP2D6 NQO1 SOD2
2
Show member pathways
11.6 DRD2 DRD3 HTR2A
3
Show member pathways
11.33 CYP1A2 CYP2D6 NQO1
4
Show member pathways
11.28 COMT CYP1A2
5 11.22 CYP1A2 NQO1
6 11.21 CYP1A2 NQO1
7
Show member pathways
11.19 COMT CYP1A2 CYP2D6
8
Show member pathways
11.1 CYP1A2 CYP2D6
9 11.06 CYP1A2 CYP2D6
10 10.97 NQO1 SOD2
11 10.8 DRD2 DRD3
12
Show member pathways
10.73 COMT CYP1A2 CYP2D6 NQO1
13
Show member pathways
10.66 COMT CYP1A2 NQO1
14
Show member pathways
10.61 CYP1A2 CYP2D6
15 10.55 COMT NQO1

GO Terms for Tardive Dyskinesia

Cellular components related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endocytic vesicle GO:0030139 9.26 DRD2 DRD3
2 dendrite GO:0030425 9.26 COMT DRD2 HTR2A NQO1
3 integral component of postsynaptic membrane GO:0099055 9.16 DRD2 HTR2A
4 dopaminergic synapse GO:0098691 8.62 DRD2 DRD3

Biological processes related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.98 CYP1A2 CYP2D6 NQO1 SOD2
2 aging GO:0007568 9.82 HTR2A NQO1 SOD2
3 response to organic cyclic compound GO:0014070 9.77 COMT CYP1A2 NQO1
4 response to ethanol GO:0045471 9.74 DRD2 DRD3 NQO1
5 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.7 DRD2 DRD3
6 circadian regulation of gene expression GO:0032922 9.7 DRD2 DRD3
7 xenobiotic metabolic process GO:0006805 9.7 CYP1A2 CYP2D6 NQO1
8 negative regulation of protein kinase B signaling GO:0051898 9.69 DRD2 DRD3
9 regulation of synaptic vesicle exocytosis GO:2000300 9.69 DRD2 HTR2A
10 visual learning GO:0008542 9.69 DRD2 DRD3
11 release of sequestered calcium ion into cytosol GO:0051209 9.68 DRD2 HTR2A
12 response to cocaine GO:0042220 9.68 DRD2 DRD3
13 positive regulation of cytokinesis GO:0032467 9.68 DRD2 DRD3
14 response to amphetamine GO:0001975 9.67 DRD2 DRD3
15 regulation of dopamine secretion GO:0014059 9.67 DRD3 HTR2A
16 response to morphine GO:0043278 9.67 DRD2 DRD3
17 negative regulation of blood pressure GO:0045776 9.66 DRD2 DRD3
18 arachidonic acid secretion GO:0050482 9.66 DRD2 DRD3
19 drug metabolic process GO:0017144 9.65 CYP1A2 CYP2D6
20 exogenous drug catabolic process GO:0042738 9.65 CYP1A2 CYP2D6
21 long-chain fatty acid biosynthetic process GO:0042759 9.64 CYP1A2 CYP2D6
22 superoxide metabolic process GO:0006801 9.64 NQO1 SOD2
23 temperature homeostasis GO:0001659 9.63 DRD2 HTR2A
24 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.63 DRD2 DRD3
25 dopamine receptor signaling pathway GO:0007212 9.62 DRD2 DRD3
26 negative regulation of protein secretion GO:0050709 9.62 DRD2 DRD3
27 synaptic transmission, dopaminergic GO:0001963 9.61 DRD2 DRD3
28 prepulse inhibition GO:0060134 9.61 DRD2 DRD3
29 positive regulation of renal sodium excretion GO:0035815 9.59 DRD2 DRD3
30 removal of superoxide radicals GO:0019430 9.58 NQO1 SOD2
31 G protein-coupled receptor internalization GO:0002031 9.58 DRD2 DRD3
32 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.56 DRD2 DRD3
33 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.55 DRD2 HTR2A
34 oxidative demethylation GO:0070989 9.54 CYP1A2 CYP2D6
35 heterocycle metabolic process GO:0046483 9.51 CYP1A2 CYP2D6
36 drug catabolic process GO:0042737 9.49 CYP1A2 CYP2D6
37 monoterpenoid metabolic process GO:0016098 9.48 CYP1A2 CYP2D6
38 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.46 DRD2 DRD3
39 negative regulation of dopamine receptor signaling pathway GO:0060160 9.43 DRD2 DRD3
40 acid secretion GO:0046717 9.4 DRD2 DRD3
41 regulation of locomotion involved in locomotory behavior GO:0090325 9.37 DRD2 DRD3
42 response to drug GO:0042493 9.35 COMT CYP1A2 DRD2 DRD3 HTR2A
43 behavioral response to cocaine GO:0048148 9.33 DRD2 DRD3 HTR2A
44 response to histamine GO:0034776 9.32 DRD2 DRD3
45 alkaloid metabolic process GO:0009820 9.26 CYP1A2 CYP2D6
46 dopamine metabolic process GO:0042417 8.8 COMT DRD2 DRD3

Molecular functions related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.73 CYP1A2 CYP2D6 NQO1 SOD2
2 monooxygenase activity GO:0004497 9.48 CYP1A2 CYP2D6
3 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.46 CYP1A2 CYP2D6
4 aromatase activity GO:0070330 9.4 CYP1A2 CYP2D6
5 adrenergic receptor activity GO:0004935 9.37 DRD2 DRD3
6 dopamine binding GO:0035240 9.32 DRD2 DRD3
7 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.26 DRD2 DRD3
8 dopamine neurotransmitter receptor activity GO:0004952 9.16 DRD2 DRD3
9 superoxide dismutase activity GO:0004784 8.96 NQO1 SOD2
10 drug binding GO:0008144 8.92 CYP2D6 DRD2 DRD3 HTR2A

Sources for Tardive Dyskinesia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....